Dedifferentiation of Metastatic Pancreatic Neuroendocrine Neoplasms Abstract #1880

Introduction: Neuroendocrine neoplasms (NENs) exhibit significant differences in growth behavior. Their metastatic disease may dedifferentiate presenting a more aggressive biological behavior
Aim(s): Prevalence of dedifferentiation of metastatic pancreatic NENs (pNENs)
Materials and methods: Dedifferentiation was defined by new biopsy of metastasis and the identification of a higher Ki-67 to increase the grade of differentiation
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Krystallenia Alexandraki

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1143 Ectopic Cushing’s Syndrome (ECS) in Patients with Neuroendocrine Neoplasms
Introduction: Ectopic Cushing syndrome (ECS) has been described in patients with neuroendocrine neoplasms (NENs)
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Krystallenia Alexandraki
Keywords: ECS
#1535 VIPomas, a Rare Entity
Introduction: VIP secreting pancreatic neuroendocrine tumors(pNETs) are rare and controlled studies are lacking.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD,PhD Georgios Boutzios
Keywords: VIPoma, pNET
#1876 Multiple Endocrine Neoplasia Type 1 (MEN1): The Experience of a Referral Center in Greece
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a genetic disorder involving mainly parathyroid, pituitary and pancreatic neuroendocrine neoplasms (pNENs)
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Krystallenia Alexandraki
Keywords: MEN1
#1014 Sunitinib Induced Hypocalcaemia During Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor used for pNET treatment.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Krystallenia Alexandraki
#1862 Biphosphonates in Metastatic Bone Disease of Neuroendocrine Neoplasms
Introduction: Metastatic bone disease (mBD) in patients with neuroendocrine neoplasms (NENs) is associated with a more aggressive behaviour
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: MD Krystallenia Alexandraki
Keywords: bone disease